Karl Utermohlen

Karl Utermohlen

Recent Articles

Elon Musk Backs Campaign to Stop Killer Robots

Tesla (TSLA) CEO Elon Musk is leading a group of founders of robotics and AI companies in helping to stop the development of killer robots.

Analysts Send Ulta Beauty Inc (ULTA) Shares Lower

Ulta Beauty (ULTA) had a difficult Monday as the company's price target was slashed by analysts, causing ULTA shares to fall more than 4%.

Solar Eclipse Deals: Where to Get Free Food and More

With the full solar eclipse having already transpired, many are seeking solar eclipse deals online. Here are some of the best offerings.

3 Stocks to Watch on Monday: Lions Gate Entertainment Corp. (USA) (LGF), Microsoft Corporation (MSFT) and Sempra Energy (SRE)

Lionsgate's (LGF) new movie tops weekend box office, Microsoft (MSFT) has plenty of gaming news and Sempra (SRE) to buy Oncor Electric.

Google Home Adds Support for Free Spotify Accounts

You can now use Google Home (GOOG,GOOGL) to stream music from your free Spotify accounts. Here's what you should know about Alphabet's move.

Poland Spring Lawsuit: Is the Bottled Beverage Really Ground Water?

A Poland Spring lawsuit is shaking Nestle's foundation as the company is being accused of selling ground water as 100% natural spring water.

Chipotle May Be Considering Chopping Chorizo From Menu

Chipotle (CMG) is considering getting rid of chorizo from its menu, as products made from the meat account for only 3% of total entree sales.

3 Stocks to Watch on Friday: Foot Locker, Inc. (FL), Gap Inc (GPS) and Applied Materials, Inc. (AMAT)

Foot Locker (FL) collapses Friday on poor quarterly results, but Gap (GPS) and Applied Materials (AMAT) should end the week on top.

Tesla, GE to Add Rooftop Solar Farms to 50 Home Depot Locations

Tesla (TSLA) and General Electric (GE) will add rooftop solar farms to 50 Home Depot locations, making more of its stores run on clean power.

Mylan N.V. (MYL) to Pay $465M in EpiPen Settlement

Mylan N.V. (MYL) will pay $465 million to settle its EpiPen case, in which it misclassified the as a generic instead of a branded product.